Administration of Metronidazole plus Amoxicillin — Competitive Intelligence Brief

Administration of Metronidazole plus Amoxicillin (Administration of Metronidazole plus Amoxicillin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial DNA (metronidazole); bacterial cell wall/penicillin-binding proteins (amoxicillin) Infectious Disease Small molecule

Target snapshot

Administration of Metronidazole plus Amoxicillin (Administration of Metronidazole plus Amoxicillin) — University of Chile. Metronidazole and amoxicillin together provide broad-spectrum antimicrobial coverage by inhibiting bacterial cell wall synthesis and DNA replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of Metronidazole plus Amoxicillin TARGET	Administration of Metronidazole plus Amoxicillin	University of Chile	marketed	Antibiotic combination	Bacterial DNA (metronidazole); bacterial cell wall/penicillin-binding proteins (amoxicillin)
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Vonoprazan+amoxicillin 7 days	Vonoprazan+amoxicillin 7 days	Xijing Hospital of Digestive Diseases	marketed	Potassium-competitive acid blocker + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan + amoxicillin	Vonoprazan + amoxicillin	The Third Xiangya Hospital of Central South University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class